Table 4.
Physicians: stated importance of attributes
| Stated importance of treatment attributes Mean score (standard deviation) (1 = not at all critical; 9 = extremely critical) |
||
|---|---|---|
| Moderate psoriasis | Severe psoriasis | |
| Efficacy | ||
| Overall perception of efficacy | 7.8 (1.4) | 7.9 (1.5) |
| Reduction in % of BSA affected | 7.8 (1.3) | 8.0 (1.3) |
| Maintenance of response over time | 7.7 (1.4) | 7.8 (1.4) |
| Reduction in symptoms associated with lesions | 7.6 (1.5) | 7.7 (1.4) |
| Reduction in redness, thickness, and scale | 7.4 (1.5) | 7.5 (1.5) |
| Improvements in patients’ QoL | 7.3 (1.9) | 7.4 (1.8) |
| Rapidity of response after initiating treatment | 6.4 (1.6) | 6.7 (1.6) |
| Improvement based on key metrics in real-world data | 6.4 (2.0) | 6.4 (2.1) |
| Improvement based on key metrics in trial data | 6.0 (2.1) | 6.1 (2.2) |
| Safety | ||
| Overall perception of safety | 8.1 (1.2) | 8.1 (1.2) |
| Low potential for AEs based on real-world data | 8.0 (1.3) | 8.0 (1.3) |
| Low potential for AEs based on clinical trial data | 7.9 (1.4) | 7.9 (1.4) |
| Patient-specific contraindications | 7.4 (1.6) | 7.4 (1.6) |
| Low potential for tolerability issues | 7.0 (1.5) | 6.9 (1.5) |
| Other | ||
| Overall perception of performance based on non-efficacy or safety metrics | 6.9 (1.7) | 7.0 (1.6) |
| Affordable/reasonable patient out-of-pocket cost | 7.8 (1.4) | 7.8 (1.4) |
| Minimal access and coverage issues | 7.6 (1.6) | 7.6 (1.6) |
| Familiarity/experience with the therapy | 7.2 (1.5) | 7.3 (1.6) |
| Maintenance dosing frequency | 6.4 (1.5) | 6.4 (1.6) |
| ROA | 6.2 (1.8) | 6.1 (1.8) |
| Ability to tailor dosing | 5.9 (1.8) | 6.0 (1.8) |
| Mechanism of action | 5.6 (1.8) | 5.6 (1.9) |